Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

MED - Medifast, Inc. Последние новости | Finranks

Home

/

MED

M

Medifast, Inc. (MED)

NYQ – Цена в реальном времени. Валюта: USD

11.77

+0.12 (1.03%)

Рынок открыт: Aug 12, 2026, 2:05 PM EDT

11.88

+0.23 (1.97%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast Q2 Earnings Call Highlights

Medifast Q2 Earnings Call Highlights

Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.

Видео

No Data

There is no data to display

Пресс-релизы

Medifast Announces Second Quarter 2026 Financial Results

Medifast Announces Second Quarter 2026 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter ended June 30, 2026. Second Quarter 2026 Revenue: $76.4 million, with revenue per active earning coach of $6,529 Independent active earning coaches of 11,700 Net loss of $3.1 million or $0.28 loss per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $169.8 million wit.